CYCN vs DARE

Cyclerion Therapeutics, Inc. vs Dare Bioscience, Inc. — Valuation Comparison 2026

CYCN

Biotechnology
Cyclerion Therapeutics, Inc.
Quality
5.5
out of 10
Value Trap
24
SAFE
Price
$3.18
Last close
Models
9/13
Active
VS

DARE

Biotechnology
Dare Bioscience, Inc.
Quality
4.4
out of 10
Value Trap
30
LOW
Price
$2.28
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CYCN Fair ValueCYCN Upside DARE Fair ValueDARE Upside
Bayesian DCF Intrinsic $1.21 -62.0% $1.22 -46.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $8.67 +172.7% $2.81 +23.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CYCN vs DARE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CYCN vs DARE — Which Stock Is More Undervalued?

CYCN scores higher with a 5.5/10 quality rating vs DARE's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cyclerion Therapeutics, Inc. (CYCN) and Dare Bioscience, Inc. (DARE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CYCN currently trades at $3.18 with a QOC of 5.5/10, while DARE trades at $2.28 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).